309 related articles for article (PubMed ID: 27533046)
1. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
Darton TC; Jones C; Blohmke CJ; Waddington CS; Zhou L; Peters A; Haworth K; Sie R; Green CA; Jeppesen CA; Moore M; Thompson BA; John T; Kingsley RA; Yu LM; Voysey M; Hindle Z; Lockhart S; Sztein MB; Dougan G; Angus B; Levine MM; Pollard AJ
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004926. PubMed ID: 27533046
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for preventing typhoid fever.
Milligan R; Paul M; Richardson M; Neuberger A
Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
[TBL] [Abstract][Full Text] [Related]
3. A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children.
Tran TH; Nguyen TD; Nguyen TT; Ninh TT; Tran NB; Nguyen VM; Tran TT; Cao TT; Pham VM; Nguyen TC; Tran TD; Pham VT; To SD; Campbell JI; Stockwell E; Schultsz C; Simmons CP; Glover C; Lam W; Marques F; May JP; Upton A; Budhram R; Dougan G; Farrar J; Nguyen VV; Dolecek C
PLoS One; 2010 Jul; 5(7):e11778. PubMed ID: 20668668
[TBL] [Abstract][Full Text] [Related]
4. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for preventing typhoid fever.
Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
[TBL] [Abstract][Full Text] [Related]
6. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
7. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations.
Kirkpatrick BD; Tenney KM; Larsson CJ; O'Neill JP; Ventrone C; Bentley M; Upton A; Hindle Z; Fidler C; Kutzko D; Holdridge R; Lapointe C; Hamlet S; Chatfield SN
J Infect Dis; 2005 Aug; 192(3):360-6. PubMed ID: 15995948
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
Kirkpatrick BD; McKenzie R; O'Neill JP; Larsson CJ; Bourgeois AL; Shimko J; Bentley M; Makin J; Chatfield S; Hindle Z; Fidler C; Robinson BE; Ventrone CH; Bansal N; Carpenter CM; Kutzko D; Hamlet S; LaPointe C; Taylor DN
Vaccine; 2006 Jan; 24(2):116-23. PubMed ID: 16140433
[TBL] [Abstract][Full Text] [Related]
9. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
10. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine.
Simanjuntak CH; Paleologo FP; Punjabi NH; Darmowigoto R; Soeprawoto ; Totosudirjo H; Haryanto P; Suprijanto E; Witham ND; Hoffman SL
Lancet; 1991 Oct; 338(8774):1055-9. PubMed ID: 1681365
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
[TBL] [Abstract][Full Text] [Related]
12. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella?
Kantele A; Pakkanen SH; Siitonen A; Karttunen R; Kantele JM
Vaccine; 2012 Nov; 30(50):7238-45. PubMed ID: 23084770
[TBL] [Abstract][Full Text] [Related]
13. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
14. In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units.
Lyon CE; Sadigh KS; Carmolli MP; Harro C; Sheldon E; Lindow JC; Larsson CJ; Martinez T; Feller A; Ventrone CH; Sack DA; DeNearing B; Fingar A; Pierce K; Dill EA; Schwartz HI; Beardsworth EE; Kilonzo B; May JP; Lam W; Upton A; Budhram R; Kirkpatrick BD
Vaccine; 2010 Apr; 28(20):3602-8. PubMed ID: 20188175
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for preventing typhoid fever.
Fraser A; Goldberg E; Acosta CJ; Paul M; Leibovici L
Cochrane Database Syst Rev; 2007 Jul; (3):CD001261. PubMed ID: 17636661
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Jin C; Gibani MM; Moore M; Juel HB; Jones E; Meiring J; Harris V; Gardner J; Nebykova A; Kerridge SA; Hill J; Thomaides-Brears H; Blohmke CJ; Yu LM; Angus B; Pollard AJ
Lancet; 2017 Dec; 390(10111):2472-2480. PubMed ID: 28965718
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
19. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
[TBL] [Abstract][Full Text] [Related]
20. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
